EN DE
Watch Shanghai Kehua Bio-Engineering Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Shanghai Kehua Bio-Engineering Co Ltd (002022) fair value: what the stock is really worth

As of Nov 5, 2026: fair value (intrinsic value) of Shanghai Kehua Bio-Engineering Co Ltd stock ¥0.76, price ¥5.21, that is 85.4% below the price, quality 43 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE000001KC9

SK Shanghai Kehua Bio-Engineering Co Ltd logo Thin data Nov 1, 2026

Shanghai Kehua Bio-Engineering Co Ltd

002022 · SHE
Very expensive, weak quality

Our calculation puts a fair price 85% below what the stock costs today.

Low debt
Profit last quarter +146% vs. a year ago.
Quality 43/100
Fair value ¥0.7600 · Strongly overvalued (−85.4%)
Weak Growth (revenue 5y −16.9 %/yr in CNY)
Loss-making · -41.7% net margin (TTM)
Negative free cash flow
Trails peers (4/12)
Narrow moat 14/100
Thin data
Watch Shanghai Kehua Bio-Engineering Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥17.49 ¥4.58 Fair Value ¥0.7600 May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 1, 2026.

How to read this chart

60‑month range ¥4.58 – ¥17.49 · fair‑value band ¥0.5000 – ¥0.9500 · the ¥5.21 price screens above the ¥0.7600 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 1, 2026.

Follow Shanghai Kehua Bio-Engineering Co in your weekly email

Every Wednesday you see whether Shanghai Kehua Bio-Engineering Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of reagents and instruments and services in China and internationally.

Show moreShow less

The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated comprehensive solutions for nucleic acid blood screening.

It also provides automatic modular and clinical chemistry analyzers and clinical chemistry reagents test menu; automatic chemiluminescence immunoassay analyzers and CLIA reagents test menu; automatic ELISA microplate readers, ELISA microplate washers, and enzyme-linked immunoassay reagents; and diagnostics kit for HIV and SARS-CoV-2 IgM/IgG antibody, HIV I/II Ab rapid tests, diagnostic kit for Hepatitis B surface antigen and Hepatitis C virus antibody, and diagnostic kit for antibody to T. Palladium.

In addition, the company offers molecular diagnostics solutions, including fully automated nucleic acid blood screening laboratory solution and nucleic acid testing and detection kits; automatic multifunctional veterinary analyzer; and mass spectrometry. It exports its products.

Further, it provides instrument products, including biochemical diagnostics, immunological diagnostics, molecular diagnostics, point-of-care testing (POCT), and mass spectrometry, advancing towards automation, digitization, and intelligence.

The company serves healthcare institutions, blood centers, disease control and prevention centers, and research organizations. Its products are used in clinical diagnostics, blood screening, public health, food safety, and scientific research applications.

The company was founded in 1981 and is headquartered in Shanghai, China.

Stock analysis

Shanghai Kehua Bio-Engineering Co Ltd (002022) currently trades at ¥5.21, while our model-based Fair Value estimate is ¥0.7600, 85% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 80/100, which puts the data coverage at low.

Scenario range: ¥0.5000 (bear) to ¥0.9500 (bull), the price of ¥5.21 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Shanghai Kehua Bio-Engineering Co Ltd reported revenue of 1.6B CNY in FY2025 versus 4.9B CNY in FY2021, a compound −23.7%/yr. Reported net income was −732M CNY in FY2025.

Key figures

Market cap 2.7B CNY (≈ $402M) Small · P/S ratio 1.68 · EPS (TTM) ¥−1.32 · Dividend yield 0.5% · Net margin −41.7% · Return on equity −24.5% · Return on assets (EBIT) 4.6% · Operating margin −9.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 14 out of 100 (medium confidence).

What moves the price

The share trades about 27% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at −85%, 002022 screens richer than that median.

Fair Value models

Bear ¥0.5000 Fair Value ¥0.7600 Bull ¥0.9500
Price ¥5.21 · Downside -85.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) ¥0.5000 ¥0.7600 ¥0.9500 54
All 1 models by family
Asset-Based
NCAV (Graham) ¥0.5000 ¥0.7600 ¥0.9500 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 43/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 8
How much profit the company makes from its sales and capital
Quality Growth 35
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 72
Debt, balance sheet and risk of trouble
Investment 88
Does it invest with discipline instead of growing at any price?
Low Volatility 79
How calm the share price moves, does not count
Price momentum 34
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 17
Distance to the 52-week high, does not count
New shares 78
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−6.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−38.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−16.9%
Start year 2020 (pandemic). Over 10 years: +3.6% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
32.7% (2020) → −20.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

002022 screens overvalued: fair value 85% below the price. Compare with Abbott Laboratories, →

Compare Shanghai Kehua Bio-Engineering Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 322 stocks

Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 43 · Below median
Fair Value upside −85.4% · Bottom 25%
Profitability
Return on assets −15.8% · Bottom 25%
Net margin (12 months) −41.7% · Bottom 25%
Operating margin (12 months) −9.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 9.1% · Above median
Dividend yield (12 months) 0.5% · Bottom 25%
Balance sheet
Debt / equity 0.02× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 1.02× · Cheaper than median
P/S (12 months) 1.59× · Cheaper than median
PEG 3.23× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 6
FUTURE (revenue growth)46 · sector 36
PAST (return on equity)0 · sector 16
HEALTH (low debt)99 · sector 98
DIVIDEND (yield)11 · sector 35

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Boston Scientific Corporation BSX $44.64 $50.40 +13% vs 002022
Stryker Corporation SYK $335.08 $373.62 +12% vs 002022
DexCom, Inc DXCM $84.46 $92.91 +10% vs 002022
STERIS plc STE $254.12 $279.53 +10% vs 002022
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.09 ¥197.22 +7% vs 002022
GE HealthCare Technologies Inc GEHC $83.75 $69.92 −17% vs 002022
Edwards Lifesciences Corporation EW $100.82 $81.94 −19% vs 002022
Abbott Laboratories, ABT $113.60 $75.28 −34% vs 002022
Medtronic plc MDT $104.84 $65.61 −37% vs 002022
Koninklijke Philips N.V PHIA €27.51 €15.23 −45% vs 002022

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Shanghai Kehua Bio-Engineering Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Shanghai Kehua Bio-Engineering Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/002022

Frequently asked questions

Is Shanghai Kehua Bio-Engineering Co Ltd (002022) overvalued or undervalued?
As of Nov 1, 2026, our model estimates a fair value of ¥0.7600 versus a price of ¥5.21, about 85% lower (overvalued).
What is the fair value of 002022?
Our model-based fair value for Shanghai Kehua Bio-Engineering Co Ltd is ¥0.7600 (as of Nov 1, 2026), built from audited fundamentals. The current price: ¥5.21.
What is the quality score of 002022?
Shanghai Kehua Bio-Engineering Co Ltd has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shanghai Kehua Bio-Engineering Co Ltd (002022)?
Our model-based price target is the fair value of ¥0.7600 (as of Nov 1, 2026) from 1 valuation models. Cautious scenario ¥0.5000, optimistic scenario ¥0.9500. It is a calculation from audited fundamentals, not an analyst target.
What is the Shanghai Kehua Bio-Engineering Co Ltd stock forecast for 2026?
Our models put fair value at ¥0.7600, about 85% lower versus a price of ¥5.21 (overvalued). Cautious scenario ¥0.5000, optimistic scenario ¥0.9500. The calculation is refreshed regularly with new filings.
What is the revenue of Shanghai Kehua Bio-Engineering Co Ltd (002022)?
Shanghai Kehua Bio-Engineering Co Ltd reported trailing-twelve-month revenue of about 1.7B CNY (latest available figure, as of Nov 1, 2026).
Does Shanghai Kehua Bio-Engineering Co Ltd pay a dividend?
Shanghai Kehua Bio-Engineering Co Ltd currently shows a dividend yield of 0.55% relative to its recent price (as of Nov 1, 2026).
What is the intrinsic value of Shanghai Kehua Bio-Engineering Co Ltd (002022)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shanghai Kehua Bio-Engineering Co Ltd it is ¥0.7600 per share (as of Nov 1, 2026), against a price of ¥5.21. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Shanghai Kehua Bio-Engineering Co Ltd stock overvalued or undervalued in 2026?
As of Nov 1, 2026, 002022 trades above its calculated fair value: price ¥5.21, fair value ¥0.7600, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 002022?
No. The price is what the market pays today (¥5.21); the fair value is what the company's own numbers justify (¥0.7600). For Shanghai Kehua Bio-Engineering Co Ltd the two are ¥4.45 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shanghai Kehua Bio-Engineering Co Ltd worth?
The market values Shanghai Kehua Bio-Engineering Co Ltd at about 2.7B CNY (market capitalisation, as of Nov 1, 2026). Per share that is ¥5.21; our models calculate a fair value of ¥0.7600 per share.
What do the bullish and bearish scenarios say about 002022?
Our models span a range for Shanghai Kehua Bio-Engineering Co Ltd: cautious scenario ¥0.5000, base ¥0.7600, optimistic ¥0.9500 per share (as of Nov 1, 2026, price ¥5.21). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of 002022?
The PEG ratio of Shanghai Kehua Bio-Engineering Co Ltd is 3.23 (P/E divided by earnings growth, as of Nov 1, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Shanghai Kehua Bio-Engineering Co Ltd (002022)?
Balance-sheet figures for Shanghai Kehua Bio-Engineering Co Ltd (as of Nov 1, 2026): return on equity −24.5%, debt of 0.02 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 002022 from its 52-week high?
Shanghai Kehua Bio-Engineering Co Ltd trades at ¥5.21, about 27% below its 52-week high of ¥7.09 and 14% above the low of ¥4.58 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of ¥0.7600 is for.
Which stocks are comparable to Shanghai Kehua Bio-Engineering Co Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shanghai Kehua Bio-Engineering Co Ltd stock attractive at the current price?
The data as of Nov 1, 2026: price ¥5.21, calculated fair value ¥0.7600 (−85%), Quality Score 43/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 002022 calculated?
We run Shanghai Kehua Bio-Engineering Co Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥0.7600, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. Shanghai Kehua Bio-Engineering Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shanghai Kehua Bio-Engineering Co Ltd (002022)?
The closing price on Nov 5, 2026 was ¥5.21. Our model-based fair value is ¥0.7600, about 85% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shanghai Kehua Bio-Engineering Co Ltd right now?
The price sits above even our optimistic bull case (¥0.9500). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (¥0.5000 to ¥0.9500) leaves room in how you read the outcome.

Key figures of Shanghai Kehua Bio-Engineering Co Ltd

How large is the market capitalisation of Shanghai Kehua Bio-Engineering Co Ltd (002022)?
The market capitalisation of Shanghai Kehua Bio-Engineering Co Ltd is 2.7B CNY (≈ $402M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shanghai Kehua Bio-Engineering Co Ltd (002022)?
The price-to-sales ratio of Shanghai Kehua Bio-Engineering Co Ltd is 1.68 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shanghai Kehua Bio-Engineering Co Ltd (002022)?
Earnings per share at Shanghai Kehua Bio-Engineering Co Ltd are ¥−1.32. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shanghai Kehua Bio-Engineering Co Ltd (002022)?
The dividend yield of Shanghai Kehua Bio-Engineering Co Ltd is 0.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shanghai Kehua Bio-Engineering Co Ltd (002022)?
The net margin of Shanghai Kehua Bio-Engineering Co Ltd is −41.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shanghai Kehua Bio-Engineering Co Ltd (002022)?
The return on equity (ROE) of Shanghai Kehua Bio-Engineering Co Ltd is −24.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shanghai Kehua Bio-Engineering Co Ltd (002022)?
On an EBIT basis the return on assets of Shanghai Kehua Bio-Engineering Co Ltd is 4.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shanghai Kehua Bio-Engineering Co Ltd (002022)?
The operating margin of Shanghai Kehua Bio-Engineering Co Ltd is −9.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shanghai Kehua Bio-Engineering Co Ltd (002022)?
Revenue at Shanghai Kehua Bio-Engineering Co Ltd is growing +9.1% versus a year earlier (3y avg −38.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shanghai Kehua Bio-Engineering Co Ltd (002022)?
Earnings per share at Shanghai Kehua Bio-Engineering Co Ltd are growing +146% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Shanghai Kehua Bio-Engineering Co Ltd (002022) generate?
The free cash flow of Shanghai Kehua Bio-Engineering Co Ltd is −117M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Shanghai Kehua Bio-Engineering Co Ltd (002022) hold?
Shanghai Kehua Bio-Engineering Co Ltd holds more cash than debt, 455M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Shanghai Kehua Bio-Engineering Co Ltd in the live analysis

One click puts Shanghai Kehua Bio-Engineering Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.